Shares of Isoray, Inc. (NYSEAMERICAN:ISR) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $1.84.
Several equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Isoray from a “sell” rating to a “hold” rating in a research note on Thursday, July 15th. Northland Securities assumed coverage on shares of Isoray in a research note on Tuesday, September 14th. They set an “outperform” rating and a $1.25 price objective for the company.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ISR. Bard Associates Inc. raised its position in shares of Isoray by 40.3% during the 2nd quarter. Bard Associates Inc. now owns 537,400 shares of the healthcare company’s stock valued at $429,000 after purchasing an additional 154,400 shares during the period. Strategic Wealth Advisors Group LLC purchased a new position in Isoray during the second quarter valued at $38,000. Walleye Capital LLC purchased a new position in Isoray during the first quarter valued at $26,000. Renaissance Technologies LLC grew its stake in Isoray by 141.8% during the first quarter. Renaissance Technologies LLC now owns 3,260,228 shares of the healthcare company’s stock valued at $3,554,000 after acquiring an additional 1,911,696 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Isoray by 163.1% during the first quarter. BlackRock Inc. now owns 3,040,560 shares of the healthcare company’s stock valued at $3,315,000 after acquiring an additional 1,884,898 shares in the last quarter. Institutional investors and hedge funds own 12.46% of the company’s stock.
Isoray (NYSEAMERICAN:ISR) last released its quarterly earnings results on Monday, September 20th. The healthcare company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Isoray had a negative net margin of 36.52% and a negative return on equity of 15.33%. During the same quarter last year, the company posted ($0.02) earnings per share. Research analysts forecast that Isoray will post -0.03 earnings per share for the current year.
IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
Featured Article: Why Invest in High-Yield Dividend Stocks?
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.